Evaluation of Liver Fibrosis Change After DAA-induced Cure of Hepatitis C in Participants With and Without HIV: ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (VHICS) - Takeaways - MDSpire

Evaluation of Liver Fibrosis Change After DAA-induced Cure of Hepatitis C in Participants With and Without HIV: ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (VHICS)

  • By

  • Marion G Peters

  • Minhee Kang

  • Robert Murphy

  • William Rosenberg

  • David L Wyles

  • on behalf of the VHICS Study Team

  • January 14, 2026

  • 0 min

Share

  • 1

    The study assessed liver fibrosis changes in HCV patients with and without HIV over 5 years post-treatment using ELF, APRI, and FIB-4 markers.

  • 2

    At study entry, 21% of participants had severe fibrosis by ELF, while only 7% and 1% were classified as severe by FIB-4 and APRI, respectively.

  • 3

    Advanced fibrosis as measured by ELF did not decrease over time, indicating persistent liver damage despite HCV cure.

  • 4

    HCV/HIV participants had a nearly twofold increased risk of clinical events compared to those with HCV alone.

  • 5

    The study highlights the importance of long-term monitoring of liver fibrosis and clinical outcomes after achieving sustained virologic response.

Original Source(s)

Evaluation of Liver Fibrosis Change After DAA-induced Cure of Hepatitis C in Participants With and Without HIV: ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (VHICS)

  • by Marion G Peters, Minhee Kang, Robert Murphy, William Rosenberg, David L Wyles, on behalf of the VHICS Study Team

  • January 14, 2026

Related Content

Correlation of ABO/Rh Blood Types with Transfusion-Related Infections in Turkish Blood Donors: An In-Depth Demographic Study (2015–2021)

The Journey to Hepatitis C Elimination in Taiwan: Insights From the Hemodialysis Population

Who Decides When a Doctor Steps Back?

Cognitive decline, credentialing, and why “I’ll know” often isn’t enough.